Home/Rare Diseases/Pulmonary Arterial Hypertension

Pulmonary & Respiratory

Pulmonary Arterial Hypertension

Also called PAH, pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a rare progressive disease of the pulmonary vasculature characterized by increased pulmonary vascular resistance and elevated right ventricular afterload, leading to right heart failure and death if untreated. PAH involves complex pathophysiology including endothelial dysfunction, vasoconstriction (abnormal nitric oxide and prostacyclin signaling), thrombosis, and vascular remodeling with progressive reduction of cross-sectional area available for blood flow.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Pulmonary Arterial Hypertension

Clinical trials are evaluating new pulmonary vasodilators, antiproliferative agents, and combination therapies targeting multiple pathways (endothelin, nitric oxide, prostacyclin). Multiple pathways-based combination therapy is now standard of care.

Try Match Me →

About Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a rare progressive disease of the pulmonary vasculature characterized by increased pulmonary vascular resistance and elevated right ventricular afterload, leading to right heart failure and death if untreated. PAH involves complex pathophysiology including endothelial dysfunction, vasoconstriction (abnormal nitric oxide and prostacyclin signaling), thrombosis, and vascular remodeling with progressive reduction of cross-sectional area available for blood flow. Idiopathic PAH (IPAH) has no identifiable cause but involves genetic predisposition (BMPR2, ALK1, ENG mutations). Secondary PAH occurs with connective tissue diseases (particularly scleroderma), chronic lung disease, liver disease, chronic hypoxia, and HIV. Patients experience dyspnea, chest pain, fatigue, and syncope. Without treatment, median survival from diagnosis is approximately 2.8 years; with modern combination therapies, outcomes have improved dramatically.

Common Symptoms

  • Shortness of breath, especially with exertion
  • Chest pain or pressure
  • Syncope (fainting) or near-syncope
  • Fatigue and weakness
  • Swelling in legs and abdomen
  • Bluish lips and skin (cyanosis) in advanced disease

Who It Affects

Can occur at any age; idiopathic PAH peaks in women ages 20-60. Heritable PAH (BMPR2 mutations) has no age predilection. Multiple risk factors including connective tissue disease, HIV, liver disease, and chronic hypoxia.

Getting Involved in Clinical Trials

Clinical trials are evaluating new pulmonary vasodilators, antiproliferative agents, and combination therapies targeting multiple pathways (endothelin, nitric oxide, prostacyclin). Multiple pathways-based combination therapy is now standard of care. The Pulmonary Hypertension Association and patient organizations provide trial information and support. If you have PAH, aggressive treatment initiation is important; most current guidelines recommend combination therapy from diagnosis. Regular cardiopulmonary monitoring including right heart catheterization helps guide therapy adjustments. Genetic testing is indicated in idiopathic PAH and familial PAH cases.

Trusted Sources

Active Clinical Trials for Pulmonary Arterial Hypertension

Finding trials for Pulmonary Arterial Hypertension...

Related Pulmonary & Respiratory Conditions

Pulmonary & Respiratory

Cystic Fibrosis

Cystic fibrosis is an autosomal recessive genetic disorder affecting the CFTR protein, which normally regulates chloride...

Pulmonary & Respiratory

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by scarring (fibrosis) of lung tissue...

Pulmonary & Respiratory

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency is a genetic disorder affecting the lungs and liver, caused by insufficient production of...